Clinical Trial

Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2025-02-21; most recent amendment 2026-05-11.
Status change: Recruiting → Active, Not Recruiting 2025-09-11
Trial Details
NCT Number NCT06846515
Lead Sponsor Arthrosi Therapeutics
Conditions Gout, Arthritis, Gouty, Hyperuricemia, Gout Chronic
Enrollment 750 participants
Start Date 2025-03-11
Primary Completion 2026-09 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2026-05-12